MYRIAD GENETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.49 USD | -0.80% |
|
-9.80% | -3.40% |
| Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
| Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.40% | 1.67B | C | ||
| -1.54% | 12.47B | B+ | ||
| -17.62% | 6.99B | B- | ||
| -2.51% | 5.1B | B | ||
| +0.53% | 4.27B | C | ||
| -6.68% | 4.27B | C | ||
| -48.27% | 3.45B | D+ | ||
| +7.09% | 2.61B | - | - | |
| -14.33% | 2.08B | B- | ||
| -12.04% | 1.48B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.
